Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Computational Biology Market by Application (Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials, Human Body Simulation Software), by Services (In-house, Contract), by End Use (Academics & Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2021-2031

A11921

Pages: 269

Charts: 60

Tables: 151

 

Computational Biology Market Research, 2031

The global computational biology market size was valued at $5.5 billion in 2021, and is projected to reach $31.5 billion by 2031, growing at a CAGR of 19.5% from 2022 to 2031. Computational biology is a branch of biology that uses computers and computer science to understand better and simulate biological structures and processes of life. It comprises the use of computational approaches (such as algorithms) to the representation and simulation of biological systems as well as the interpretation of experimental data on a massive scale.

Get more information on this report : Request Sample Pages

It is an interdisciplinary field that develops and applies computational methods to analyze large collections of biological data, such as genetic sequences, cell populations or protein samples, to make new predictions or discover new biology. The computational methods used include analytical methods, mathematical modelling, and simulation.

The models of biological systems are constructed from experimental measurements. These models describe what biological tasks are carried out by particular nucleic acid or peptide sequences, which gene (or genes) when expressed produce a particular phenotype or behavior, what sequence of changes in gene or protein expression or localization led to a particular disease, and how changes in cell organization influence cell behavior.

Computational biology is helpful in various ways; for instance, along with bioinformatics technology, it helps in accelerating to revel genome and protein structure, variant calling, mutation, and other biological characteristics of SARS-CoV-2. Bioinformatics analysis helps to find the evidence of the origin, host, and evolution of the virus. Furthermore, molecular dynamics simulation, molecular docking, and artificial intelligence (AI) technology of bioinformatics methods can accelerate the development of drugs. Bioinformatics technologies further can develop the effectiveness and safety of the vaccines through reverse vaccinology, immuno-informatics, and structural vaccinology.

The global competitional biology market is expected to witness moderate growth during the forecast period, owing to increase in demand of pharmacovigilance; rise in adoption and development of advanced software for drug discovery; and disease modeling of various diseases such as cardiovascular, cancer, and other infectious diseases. Furthermore, surge in demand for tools of computational biology in various fields such as genomics, epi-genomics, proteomics, and meta-genomics for better understanding of protein structure and interaction provides significant opportunities for existing players and new entrants.

However, complications such as allergic reactions that cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, high initial cost & maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce are expected to be the significant restraints of the global market.

Computational Biology Market Segmentation:

The computational biology market is segmented into Application, Services and End Use and region. By application, the market is segregated into cellular & biological simulation, drug discovery & disease modeling, pre-clinical drug development, clinical trials, and human body simulation software.

The cellular & biological simulation is sub-segmented into computer, genomics, computational proteomics, pharmacogenomics, and others. The drug discovery & disease modeling segregated into target identification, target validation, lead discovery, and lead optimization. The pre-clinical drug development segmented into pharmacokinetics and pharmacodynamics. The clinical trials are subcategorized into phase I, phase II, and phase III.

On the basis of services, the segment is divided into in-house services and contract. On the basis of end use the segment is divided into academics & research and commercials. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Application Segment Review

[APPLICATIONGRAPH]

By application segment, the computational biology market size is divided into cellular and biological simulation, drug discovery & disease modeling, pre-clinical drug development, clinical trials and human body simulation software. The cellular & biological simulation segment was the highest revenue contributor to the market. Owing to increase in demand of virtual cells open-source software, computer genomics & computational proteomics also many private and commercial cloud platforms work in collaboration with governmental and public entities to provide cellular & biological simulation service are expected to drive the market growth.

The drug discovery & disease modeling segment is estimated to be the fastest growing segment during the computational biology market forecast. Owing to increase in number of drug development and rise in awareness regarding target selection by using various methods such as assay and readers, automation and high content screening.

Services Segment Review

[SERVICESGRAPH]

By services, the contract segment was the highest revenue contributor to the market. This is owing to the fact that contract services are cheap when compared to the in-house services provided worldwide. Contract Research Organization (CRO) pro service providers work with clients to develop a customized plan as per the requirements therefore, act as a driver to boost the growth of the market.

The in-house segment is estimated to be the fastest growing segment. In-house service provides a company with greater control over the execution of in-house tasks, since it is the direct employer-based services also because of the advantages such as cost and time saving.

End use Segment Review

[ENDUSEGRAPH]

By end use, the commercial segment was the highest revenue contributor to the market. Due to increasing investment in Research and Development (R&D) in genetic engineering and new drug discovery by public as well as private companies, which contribute in the growing demand for computational biology significantly.

The academics & research segment is fastest growing segment during the forecast period. Owing to increase in drug discovery & disease modeling process for various chronic diseases such as cancer, diabetes, cardiovascular diseases, and respiratory disorders that create demand for this segment also increase in demand for predictive models, usage in population-based sequencing projects such as human genome project, and government funding is contributing in the growth of computational biology market analysis.

Region Segment Review

[REGIONGRAPH]

Region wise, the computational biology market trend is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the largest shareholder in the computational biology market in 2021. Increase in demand of pharmacovigilance for the pre-clinical drug development and to conduct clinical trials, R&D investments, and supportive government initiatives are the major factors that drive growth of the computational biology market share.

LAMEA is estimated to grow fastest during the forecast period. Rise in number of product approval, increase in number of clinical trials procedures, surge in demand for bioinformatics tools & services emphasis of prominent players in enhancing their presence and high demand for advanced computational biology software in the region.

Key players operating in the global computational biology market growth include Altaris Capital Partner, Compugen Ltd., Certara, Genedata AG, Dassault Systems, DNAnexus, Nimbus Discovery, Instem, Rosa & co. Ltd., and Simulation Plus.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the computational biology market, and the current computational biology market trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis of the market from 2022 to 2031 to enable stakeholders to capitalize on the prevailing market computational biology market opportunity.
  • Extensive analysis of the market based on procedures and services assists to understand the trends in the computational biology industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Key Market Segments

  • By Application
    • Cellular & Biological Simulation
    • Drug Discovery & Disease Modelling
    • Preclinical Drug Development
    • Clinical Trials
    • Human Body Simulation Software
  • By Services
    • Contract
    • In-house
  • By End Use
    • Academics & Research
    • Commercial
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA


Key Market Players

  • Rhenovia Pharma SAS
  • Chemical Computing Group Inc.
  • Entelos
  • Rhenovia Pharma SAS & Leadscope Inc.
  • Simulation Plus Inc.
  • Genedata AG
  • Nimbus Discovery LLC
  • Compugen Ltd.
  • Certara
  • Insilico Biotechnology AG
  • Accelrys
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Cellular & Biological Simulation

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Drug Discovery & Disease Modelling

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Preclinical Drug Development

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

    • 4.5 Clinical Trials

      • 4.5.1 Key market trends, growth factors and opportunities

      • 4.5.2 Market size and forecast, by region

      • 4.5.3 Market analysis by country

    • 4.6 Human Body Simulation Software

      • 4.6.1 Key market trends, growth factors and opportunities

      • 4.6.2 Market size and forecast, by region

      • 4.6.3 Market analysis by country

  • CHAPTER 5: COMPUTATIONAL BIOLOGY MARKET, BY SERVICES

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 In-house

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Contract

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

  • CHAPTER 6: COMPUTATIONAL BIOLOGY MARKET, BY END USE

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Academics & Research

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Commercial

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

  • CHAPTER 7: COMPUTATIONAL BIOLOGY MARKET, BY REGION

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 North America

      • 7.2.1 Key trends and opportunities

      • 7.2.2 North America Market size and forecast, by Application

      • 7.2.3 North America Market size and forecast, by Services

      • 7.2.4 North America Market size and forecast, by End Use

      • 7.2.5 North America Market size and forecast, by country

        • 7.2.5.1 U.S.
          • 7.2.5.1.1 Market size and forecast, by Application
          • 7.2.5.1.2 Market size and forecast, by Services
          • 7.2.5.1.3 Market size and forecast, by End Use
        • 7.2.5.2 Canada
          • 7.2.5.2.1 Market size and forecast, by Application
          • 7.2.5.2.2 Market size and forecast, by Services
          • 7.2.5.2.3 Market size and forecast, by End Use
        • 7.2.5.3 Mexico
          • 7.2.5.3.1 Market size and forecast, by Application
          • 7.2.5.3.2 Market size and forecast, by Services
          • 7.2.5.3.3 Market size and forecast, by End Use
    • 7.3 Europe

      • 7.3.1 Key trends and opportunities

      • 7.3.2 Europe Market size and forecast, by Application

      • 7.3.3 Europe Market size and forecast, by Services

      • 7.3.4 Europe Market size and forecast, by End Use

      • 7.3.5 Europe Market size and forecast, by country

        • 7.3.5.1 Germany
          • 7.3.5.1.1 Market size and forecast, by Application
          • 7.3.5.1.2 Market size and forecast, by Services
          • 7.3.5.1.3 Market size and forecast, by End Use
        • 7.3.5.2 France
          • 7.3.5.2.1 Market size and forecast, by Application
          • 7.3.5.2.2 Market size and forecast, by Services
          • 7.3.5.2.3 Market size and forecast, by End Use
        • 7.3.5.3 United Kingdom
          • 7.3.5.3.1 Market size and forecast, by Application
          • 7.3.5.3.2 Market size and forecast, by Services
          • 7.3.5.3.3 Market size and forecast, by End Use
        • 7.3.5.4 Italy
          • 7.3.5.4.1 Market size and forecast, by Application
          • 7.3.5.4.2 Market size and forecast, by Services
          • 7.3.5.4.3 Market size and forecast, by End Use
        • 7.3.5.5 Spain
          • 7.3.5.5.1 Market size and forecast, by Application
          • 7.3.5.5.2 Market size and forecast, by Services
          • 7.3.5.5.3 Market size and forecast, by End Use
        • 7.3.5.6 Rest of Europe
          • 7.3.5.6.1 Market size and forecast, by Application
          • 7.3.5.6.2 Market size and forecast, by Services
          • 7.3.5.6.3 Market size and forecast, by End Use
    • 7.4 Asia-Pacific

      • 7.4.1 Key trends and opportunities

      • 7.4.2 Asia-Pacific Market size and forecast, by Application

      • 7.4.3 Asia-Pacific Market size and forecast, by Services

      • 7.4.4 Asia-Pacific Market size and forecast, by End Use

      • 7.4.5 Asia-Pacific Market size and forecast, by country

        • 7.4.5.1 Japan
          • 7.4.5.1.1 Market size and forecast, by Application
          • 7.4.5.1.2 Market size and forecast, by Services
          • 7.4.5.1.3 Market size and forecast, by End Use
        • 7.4.5.2 China
          • 7.4.5.2.1 Market size and forecast, by Application
          • 7.4.5.2.2 Market size and forecast, by Services
          • 7.4.5.2.3 Market size and forecast, by End Use
        • 7.4.5.3 Australia
          • 7.4.5.3.1 Market size and forecast, by Application
          • 7.4.5.3.2 Market size and forecast, by Services
          • 7.4.5.3.3 Market size and forecast, by End Use
        • 7.4.5.4 India
          • 7.4.5.4.1 Market size and forecast, by Application
          • 7.4.5.4.2 Market size and forecast, by Services
          • 7.4.5.4.3 Market size and forecast, by End Use
        • 7.4.5.5 South Korea
          • 7.4.5.5.1 Market size and forecast, by Application
          • 7.4.5.5.2 Market size and forecast, by Services
          • 7.4.5.5.3 Market size and forecast, by End Use
        • 7.4.5.6 Rest of Asia-Pacific
          • 7.4.5.6.1 Market size and forecast, by Application
          • 7.4.5.6.2 Market size and forecast, by Services
          • 7.4.5.6.3 Market size and forecast, by End Use
    • 7.5 LAMEA

      • 7.5.1 Key trends and opportunities

      • 7.5.2 LAMEA Market size and forecast, by Application

      • 7.5.3 LAMEA Market size and forecast, by Services

      • 7.5.4 LAMEA Market size and forecast, by End Use

      • 7.5.5 LAMEA Market size and forecast, by country

        • 7.5.5.1 Brazil
          • 7.5.5.1.1 Market size and forecast, by Application
          • 7.5.5.1.2 Market size and forecast, by Services
          • 7.5.5.1.3 Market size and forecast, by End Use
        • 7.5.5.2 Saudi Arabia
          • 7.5.5.2.1 Market size and forecast, by Application
          • 7.5.5.2.2 Market size and forecast, by Services
          • 7.5.5.2.3 Market size and forecast, by End Use
        • 7.5.5.3 South Africa
          • 7.5.5.3.1 Market size and forecast, by Application
          • 7.5.5.3.2 Market size and forecast, by Services
          • 7.5.5.3.3 Market size and forecast, by End Use
        • 7.5.5.4 Rest of LAMEA
          • 7.5.5.4.1 Market size and forecast, by Application
          • 7.5.5.4.2 Market size and forecast, by Services
          • 7.5.5.4.3 Market size and forecast, by End Use
  • CHAPTER 8: COMPANY LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Key developments

  • CHAPTER 9: COMPANY PROFILES

    • 9.1 Chemical Computing Group Inc.

      • 9.1.1 Company overview

      • 9.1.2 Company snapshot

      • 9.1.3 Operating business segments

      • 9.1.4 Product portfolio

      • 9.1.5 Business performance

      • 9.1.6 Key strategic moves and developments

    • 9.2 Compugen Ltd.

      • 9.2.1 Company overview

      • 9.2.2 Company snapshot

      • 9.2.3 Operating business segments

      • 9.2.4 Product portfolio

      • 9.2.5 Business performance

      • 9.2.6 Key strategic moves and developments

    • 9.3 Simulation Plus Inc.

      • 9.3.1 Company overview

      • 9.3.2 Company snapshot

      • 9.3.3 Operating business segments

      • 9.3.4 Product portfolio

      • 9.3.5 Business performance

      • 9.3.6 Key strategic moves and developments

    • 9.4 Genedata AG

      • 9.4.1 Company overview

      • 9.4.2 Company snapshot

      • 9.4.3 Operating business segments

      • 9.4.4 Product portfolio

      • 9.4.5 Business performance

      • 9.4.6 Key strategic moves and developments

    • 9.5 Certara

      • 9.5.1 Company overview

      • 9.5.2 Company snapshot

      • 9.5.3 Operating business segments

      • 9.5.4 Product portfolio

      • 9.5.5 Business performance

      • 9.5.6 Key strategic moves and developments

    • 9.6 Insilico Biotechnology AG

      • 9.6.1 Company overview

      • 9.6.2 Company snapshot

      • 9.6.3 Operating business segments

      • 9.6.4 Product portfolio

      • 9.6.5 Business performance

      • 9.6.6 Key strategic moves and developments

    • 9.7 Accelrys

      • 9.7.1 Company overview

      • 9.7.2 Company snapshot

      • 9.7.3 Operating business segments

      • 9.7.4 Product portfolio

      • 9.7.5 Business performance

      • 9.7.6 Key strategic moves and developments

    • 9.8 Rhenovia Pharma SAS

      • 9.8.1 Company overview

      • 9.8.2 Company snapshot

      • 9.8.3 Operating business segments

      • 9.8.4 Product portfolio

      • 9.8.5 Business performance

      • 9.8.6 Key strategic moves and developments

    • 9.9 Entelos

      • 9.9.1 Company overview

      • 9.9.2 Company snapshot

      • 9.9.3 Operating business segments

      • 9.9.4 Product portfolio

      • 9.9.5 Business performance

      • 9.9.6 Key strategic moves and developments

    • 9.10 Nimbus Discovery LLC

      • 9.10.1 Company overview

      • 9.10.2 Company snapshot

      • 9.10.3 Operating business segments

      • 9.10.4 Product portfolio

      • 9.10.5 Business performance

      • 9.10.6 Key strategic moves and developments

    • 9.11 Rhenovia Pharma SAS & Leadscope Inc.

      • 9.11.1 Company overview

      • 9.11.2 Company snapshot

      • 9.11.3 Operating business segments

      • 9.11.4 Product portfolio

      • 9.11.5 Business performance

      • 9.11.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 2. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CELLULAR & BIOLOGICAL SIMULATION, BY REGION , 2021-2031,($MILLION)
    TABLE 3. COMPUTATIONAL BIOLOGY MARKET FOR CELLULAR & BIOLOGICAL SIMULATION BY COUNTRY, 2021-2031,($MILLION)
    TABLE 4. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR DRUG DISCOVERY & DISEASE MODELLING, BY REGION , 2021-2031,($MILLION)
    TABLE 5. COMPUTATIONAL BIOLOGY MARKET FOR DRUG DISCOVERY & DISEASE MODELLING BY COUNTRY, 2021-2031,($MILLION)
    TABLE 6. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION , 2021-2031,($MILLION)
    TABLE 7. COMPUTATIONAL BIOLOGY MARKET FOR PRECLINICAL DRUG DEVELOPMENT BY COUNTRY, 2021-2031,($MILLION)
    TABLE 8. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CLINICAL TRIALS, BY REGION , 2021-2031,($MILLION)
    TABLE 9. COMPUTATIONAL BIOLOGY MARKET FOR CLINICAL TRIALS BY COUNTRY, 2021-2031,($MILLION)
    TABLE 10. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR HUMAN BODY SIMULATION SOFTWARE, BY REGION , 2021-2031,($MILLION)
    TABLE 11. COMPUTATIONAL BIOLOGY MARKET FOR HUMAN BODY SIMULATION SOFTWARE BY COUNTRY, 2021-2031,($MILLION)
    TABLE 12. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 13. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR IN-HOUSE, BY REGION , 2021-2031,($MILLION)
    TABLE 14. COMPUTATIONAL BIOLOGY MARKET FOR IN-HOUSE BY COUNTRY, 2021-2031,($MILLION)
    TABLE 15. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR CONTRACT, BY REGION , 2021-2031,($MILLION)
    TABLE 16. COMPUTATIONAL BIOLOGY MARKET FOR CONTRACT BY COUNTRY, 2021-2031,($MILLION)
    TABLE 17. GLOBAL COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 18. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR ACADEMICS & RESEARCH, BY REGION , 2021-2031,($MILLION)
    TABLE 19. COMPUTATIONAL BIOLOGY MARKET FOR ACADEMICS & RESEARCH BY COUNTRY, 2021-2031,($MILLION)
    TABLE 20. COMPUTATIONAL BIOLOGY MARKET REVENUE, FOR COMMERCIAL, BY REGION , 2021-2031,($MILLION)
    TABLE 21. COMPUTATIONAL BIOLOGY MARKET FOR COMMERCIAL BY COUNTRY, 2021-2031,($MILLION)
    TABLE 22. COMPUTATIONAL BIOLOGY MARKET, BY REGION, 2021-2031,($MILLION)
    TABLE 23. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 24. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 25. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 26. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
    TABLE 27. U.S. COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 28. U.S. COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 29. U.S. COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 30. CANADA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 31. CANADA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 32. CANADA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 33. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 34. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 35. MEXICO COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 36. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 37. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 38. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 39. EUROPE COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
    TABLE 40. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 41. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 42. GERMANY COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 43. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 44. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 45. FRANCE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 46. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 47. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 48. UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 49. ITALY COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 50. ITALY COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 51. ITALY COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 52. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 53. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 54. SPAIN COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 55. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 56. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 57. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 58. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 59. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 60. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 61. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
    TABLE 62. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 63. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 64. JAPAN COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 65. CHINA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 66. CHINA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 67. CHINA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 68. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 69. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 70. AUSTRALIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 71. INDIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 72. INDIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 73. INDIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 74. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 75. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 76. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 77. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 78. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 79. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 80. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 81. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 82. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 83. LAMEA COMPUTATIONAL BIOLOGY MARKET, BY COUNTRY, 2021-2031,($MILLION)
    TABLE 84. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 85. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 86. BRAZIL COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 87. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 88. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 89. SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 90. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 91. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 92. SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 93. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 94. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY SERVICES, 2021-2031,($MILLION)
    TABLE 95. REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET, BY END USE, 2021-2031,($MILLION)
    TABLE 96.CHEMICAL COMPUTING GROUP INC.: COMPANY SNAPSHOT
    TABLE 97.CHEMICAL COMPUTING GROUP INC.: OPERATING SEGMENTS
    TABLE 98.CHEMICAL COMPUTING GROUP INC.: PRODUCT PORTFOLIO
    TABLE 99.CHEMICAL COMPUTING GROUP INC.: NET SALES,
    TABLE 100.CHEMICAL COMPUTING GROUP INC.: KEY STRATERGIES
    TABLE 101.COMPUGEN LTD.: COMPANY SNAPSHOT
    TABLE 102.COMPUGEN LTD.: OPERATING SEGMENTS
    TABLE 103.COMPUGEN LTD.: PRODUCT PORTFOLIO
    TABLE 104.COMPUGEN LTD.: NET SALES,
    TABLE 105.COMPUGEN LTD.: KEY STRATERGIES
    TABLE 106.SIMULATION PLUS INC.: COMPANY SNAPSHOT
    TABLE 107.SIMULATION PLUS INC.: OPERATING SEGMENTS
    TABLE 108.SIMULATION PLUS INC.: PRODUCT PORTFOLIO
    TABLE 109.SIMULATION PLUS INC.: NET SALES,
    TABLE 110.SIMULATION PLUS INC.: KEY STRATERGIES
    TABLE 111.GENEDATA AG: COMPANY SNAPSHOT
    TABLE 112.GENEDATA AG: OPERATING SEGMENTS
    TABLE 113.GENEDATA AG: PRODUCT PORTFOLIO
    TABLE 114.GENEDATA AG: NET SALES,
    TABLE 115.GENEDATA AG: KEY STRATERGIES
    TABLE 116.CERTARA: COMPANY SNAPSHOT
    TABLE 117.CERTARA: OPERATING SEGMENTS
    TABLE 118.CERTARA: PRODUCT PORTFOLIO
    TABLE 119.CERTARA: NET SALES,
    TABLE 120.CERTARA: KEY STRATERGIES
    TABLE 121.INSILICO BIOTECHNOLOGY AG: COMPANY SNAPSHOT
    TABLE 122.INSILICO BIOTECHNOLOGY AG: OPERATING SEGMENTS
    TABLE 123.INSILICO BIOTECHNOLOGY AG: PRODUCT PORTFOLIO
    TABLE 124.INSILICO BIOTECHNOLOGY AG: NET SALES,
    TABLE 125.INSILICO BIOTECHNOLOGY AG: KEY STRATERGIES
    TABLE 126.ACCELRYS: COMPANY SNAPSHOT
    TABLE 127.ACCELRYS: OPERATING SEGMENTS
    TABLE 128.ACCELRYS: PRODUCT PORTFOLIO
    TABLE 129.ACCELRYS: NET SALES,
    TABLE 130.ACCELRYS: KEY STRATERGIES
    TABLE 131.RHENOVIA PHARMA SAS: COMPANY SNAPSHOT
    TABLE 132.RHENOVIA PHARMA SAS: OPERATING SEGMENTS
    TABLE 133.RHENOVIA PHARMA SAS: PRODUCT PORTFOLIO
    TABLE 134.RHENOVIA PHARMA SAS: NET SALES,
    TABLE 135.RHENOVIA PHARMA SAS: KEY STRATERGIES
    TABLE 136.ENTELOS: COMPANY SNAPSHOT
    TABLE 137.ENTELOS: OPERATING SEGMENTS
    TABLE 138.ENTELOS: PRODUCT PORTFOLIO
    TABLE 139.ENTELOS: NET SALES,
    TABLE 140.ENTELOS: KEY STRATERGIES
    TABLE 141.NIMBUS DISCOVERY LLC: COMPANY SNAPSHOT
    TABLE 142.NIMBUS DISCOVERY LLC: OPERATING SEGMENTS
    TABLE 143.NIMBUS DISCOVERY LLC: PRODUCT PORTFOLIO
    TABLE 144.NIMBUS DISCOVERY LLC: NET SALES,
    TABLE 145.NIMBUS DISCOVERY LLC: KEY STRATERGIES
    TABLE 146.RHENOVIA PHARMA SAS & LEADSCOPE INC.: COMPANY SNAPSHOT
    TABLE 147.RHENOVIA PHARMA SAS & LEADSCOPE INC.: OPERATING SEGMENTS
    TABLE 148.RHENOVIA PHARMA SAS & LEADSCOPE INC.: PRODUCT PORTFOLIO
    TABLE 149.RHENOVIA PHARMA SAS & LEADSCOPE INC.: NET SALES,
    TABLE 150.RHENOVIA PHARMA SAS & LEADSCOPE INC.: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.COMPUTATIONAL BIOLOGY MARKET SEGMENTATION
    FIGURE 2.COMPUTATIONAL BIOLOGY MARKET,2021-2031
    FIGURE 3.COMPUTATIONAL BIOLOGY MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.COMPUTATIONAL BIOLOGY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.COMPUTATIONAL BIOLOGY MARKET,BY APPLICATION,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CELLULAR & BIOLOGICAL SIMULATION COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DRUG DISCOVERY & DISEASE MODELLING COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PRECLINICAL DRUG DEVELOPMENT COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIALS COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HUMAN BODY SIMULATION SOFTWARE COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 18.COMPUTATIONAL BIOLOGY MARKET,BY SERVICES,2021(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF IN-HOUSE COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CONTRACT COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 21.COMPUTATIONAL BIOLOGY MARKET,BY END USE,2021(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ACADEMICS & RESEARCH COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF COMMERCIAL COMPUTATIONAL BIOLOGY MARKET,2021-2031(%)
    FIGURE 24.COMPUTATIONAL BIOLOGY MARKET BY REGION,2021
    FIGURE 25.U.S. COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 26.CANADA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 27.MEXICO COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 28.GERMANY COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 29.FRANCE COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 30.UNITED KINGDOM COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 31.ITALY COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 32.SPAIN COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 33.REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 34.JAPAN COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 35.CHINA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 36.AUSTRALIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 37.INDIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 38.SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 39.REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 40.BRAZIL COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 41.SAUDI ARABIA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 42.SOUTH AFRICA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 43.REST OF LAMEA COMPUTATIONAL BIOLOGY MARKET,2021-2031($MILLION)
    FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 48.COMPETITIVE DASHBOARD
    FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 50.CHEMICAL COMPUTING GROUP INC..: NET SALES ,($MILLION)
    FIGURE 51.COMPUGEN LTD..: NET SALES ,($MILLION)
    FIGURE 52.SIMULATION PLUS INC..: NET SALES ,($MILLION)
    FIGURE 53.GENEDATA AG.: NET SALES ,($MILLION)
    FIGURE 54.CERTARA.: NET SALES ,($MILLION)
    FIGURE 55.INSILICO BIOTECHNOLOGY AG.: NET SALES ,($MILLION)
    FIGURE 56.ACCELRYS.: NET SALES ,($MILLION)
    FIGURE 57.RHENOVIA PHARMA SAS.: NET SALES ,($MILLION)
    FIGURE 58.ENTELOS.: NET SALES ,($MILLION)
    FIGURE 59.NIMBUS DISCOVERY LLC.: NET SALES ,($MILLION)
    FIGURE 60.RHENOVIA PHARMA SAS & LEADSCOPE INC..: NET SALES ,($MILLION)

Purchase Full Report of
Computational Biology Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue